報價延遲最少15分鐘:2024/05/01 20:46 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.92 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.53/-0.90
|
|
企業價值
117.65M
|
| 資產負債 |
|
每股賬面淨值
0.54
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
3.50M
|
|
每股收益
0.13
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/01 20:46 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM. |